Delivery Order SPE2DB22D2206-SPE2DB25FJD86
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, valued at $36,394.49. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a non-competitive award under the company's existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency awarded a $3,717.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This delivery order is issued under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,088.91 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 mg capsules. This non-competitive, firm fixed price delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child contract under a larger vehicle, this delivery order represents a...
- The Defense Logistics Agency awarded a $5,756.16 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of 36,000 unit capsules of Creon DR 100s, with delivery required by July 23, 2025. This non-set-aside competitive award will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this delivery order as a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Creon DR 36,000 unit capsules (100 count bottles) valued at $4,260.68 under a firm fixed-price contract type. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of July 25, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Creon DR 36,000 unit capsules in units of 100, with a contract ceiling value of $2,335.13 and an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 36,000 unit capsules of the pharmaceutical product CREON DR. The $2,458.62 contract has an ultimate completion date of April 9, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle...
- The Defense Logistics Agency awarded a $2,376.88 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of 36,000 unit capsules of Creon 100s, a pancreatic enzyme replacement therapy. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 36,000 units of CREON DR 4563849287 capsules in 100-count packages. The potential value of this contract is $1,366.89 with a completion date of March 5, 2024. Amerisourcebergen Drug Corp is the prime contractor and no set-aside designation was used for this award. This delivery order is part of a larger indefinite...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJD86Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,406.80 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s, with performance at the contractor's facility in Conshohocken, Pennsylvania. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The contract was issued on July 30, 2025, under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its comprehensive pharmaceutical supply portfolio. As the prime contractor, AmerisourceBergen leverages its large IDC with DLA to fulfill delivery orders for military and veteran healthcare systems, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare organizations. This particular delivery order for Creon DR—a pancreatic enzyme replacement therapy—exemplifies the company's role in supplying specialized pharmaceutical products across multiple therapeutic domains to support federal medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 7/30/25 |